Year None2023202220212020201920182017201620152014201320122011 Jun 05, 2023 Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) Read More May 24, 2023 Ultragenyx Issues 2022 Environmental, Social and Governance (ESG) Report Read More May 19, 2023 Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit Read More May 18, 2023 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Read More May 17, 2023 Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S. Read More May 08, 2023 Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting Read More May 05, 2023 Ultragenyx to Present at Bank of America’s 2023 Health Care Conference Read More May 04, 2023 Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update Read More Apr 27, 2023 Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update Read More Apr 19, 2023 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Read More Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
Jun 05, 2023 Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) Read More
May 19, 2023 Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit Read More
May 17, 2023 Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S. Read More
May 08, 2023 Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting Read More
Apr 27, 2023 Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update Read More
